- Reviews & Citations
VTN,V75,VN,Vitronectin,S-protein,Serum-spreading factor
Biotinylated Human Vitronectin, Tag Free, primary amine labeling (VIN-H8113) is expressed from E. coli cells. It contains AA Asp 20 - Arg 398 (Accession # P04004-1).
Predicted N-terminus: Met
This protein carries no "tag"
The protein has a calculated MW of 43.2 kDa. The protein migrates as 47-55 kDa under reducing (R) condition (SDS-PAGE).
The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with biotins using standard chemical labeling method. A standard biotin reagent (13.5 angstroms) is used in this product.
Passed as determined by the HABA assay / binding ELISA.
Less than 1.0 EU per μg by the LAL method.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Vitronectin is also known as S-protein, VN, VTN, V75. Vitronectin, a multifunctional glycoprotein, is involved in coagulation, inhibition of the formation of the membrane attack complex (MAC), cell adhesion and migration, wound healing, and tissue remodeling. The primary cellular source of vitronectin is hepatocytes. Blocking of Hic(a member of the pneumococcal surface protein C (PspC) family) by specific antiserum or genetic deletion significantly reduced pneumococcal binding to soluble and immobilised vitronectin and to Factor H, respectively. In addition, Vitronectin interact with glycosaminoglycans and proteoglycans. Is recognized by certain members of the integrin family and serves as a cell-to-substrate adhesion molecule. Inhibitor of the membrane-damaging effect of the terminal cytolytic complement pathway.